Phathom Pharmaceuticals, Inc.
PHAT
$9.89
-$0.11-1.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 54.51% | 33.82% | 19.12% | -11.12% | -40.21% |
| Total Depreciation and Amortization | -25.33% | -20.38% | -11.31% | 2.23% | 17.88% |
| Total Amortization of Deferred Charges | 30.99% | 37.50% | 33.11% | 27.19% | 30.13% |
| Total Other Non-Cash Items | -24.81% | -20.87% | -25.01% | -15.46% | -5.39% |
| Change in Net Operating Assets | 88.85% | 19.10% | -355.75% | -139.97% | -297.39% |
| Cash from Operations | 65.51% | 37.48% | 8.85% | -27.49% | -69.34% |
| Capital Expenditure | -140.71% | -69.63% | 75.70% | 89.07% | 92.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -140.71% | -69.63% | 75.70% | 89.07% | 92.26% |
| Total Debt Issued | 250.00% | -- | -89.97% | -89.97% | -77.69% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.67% | -98.67% | -98.63% | 362,938.24% | -12.82% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -61.62% | -100.16% | -92.99% | -39.93% | -52.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.42% | -98.85% | -264.89% | -526.14% | -156.36% |